Skip to main content
. 2017 Nov 1;12(11):e0187173. doi: 10.1371/journal.pone.0187173

Fig 2. Efficacy of dasatinib in CRC PDX models.

Fig 2

A) Seventeen colorectal cancer explants were treated with dasatinib and tumor size was evaluated twice per week. A TGI was calculated by relative tumor growth of treated mice divided by relative tumor growth of control mice x 100. CRC explants that exhibited a TGI < 50% were considered sensitive and TGI > 50% were considered resistant to dasatinib. B-C) Two explants (CRC036 and CRC047) demonstrated sensitivity to dasatinib. Columns, mean (n = 10 tumors per group); bars, SEM; and *, significance (P < 0.05) compared with control.